What are the possible causes of an elevated International Normalized Ratio (INR) in a patient with left ventricular dysfunction who is on chronic warfarin therapy?

Causes of Deranged INR in Patients on Chronic Warfarin

In a patient with left ventricular dysfunction on chronic warfarin therapy, an elevated INR is most commonly caused by drug interactions (particularly antibiotics and CYP2C9 inhibitors), hepatic dysfunction, heart failure decompensation, dietary changes, intercurrent illness, or medication non-adherence. 1, 2

Primary Mechanisms of INR Elevation

Drug Interactions (Most Common)

Drug interactions represent the most frequent cause of INR derangement, with over 500 documented warfarin interactions 1. The mechanism varies:

Pharmacokinetic interactions:

• CYP2C9 inhibitors (metabolize the more potent S-warfarin): sulfamethoxazole/trimethoprim, metronidazole - these can nearly double bleeding risk and warrant preemptive 25-33% warfarin dose reductions 1
• CYP3A4 inhibitors (metabolize R-warfarin): clarithromycin, erythromycin, fluoroquinolones 1
• All antibiotics alter gut microbiome vitamin K production, potentiating warfarin effects regardless of enzyme interactions 1

Pharmacodynamic interactions:

• NSAIDs and aspirin inhibit platelet aggregation and cause GI bleeding 2
• Drugs with antiplatelet/anticoagulant properties create additive effects 2

Heart Failure and Left Ventricular Dysfunction

Patients with left ventricular systolic dysfunction (LVEF <40%) require 11% lower warfarin doses 3. Decompensated heart failure is a particularly high-risk state - it increases the odds of prolonged INR elevation by 2.79-fold 4. The mechanism involves:

• Hepatic congestion impairing warfarin metabolism
• Reduced hepatic synthesis of clotting factors
• Decreased drug clearance

Hepatic Dysfunction

Liver disease causes INR elevation through two mechanisms 2:

• Impaired synthesis of vitamin K-dependent clotting factors
• Decreased warfarin metabolism

Patient-Specific Risk Factors

Age-related factors:

• Each decade of life increases odds of prolonged INR elevation by 1.18-fold 4
• Elderly patients (≥60 years) exhibit greater PT/INR response to warfarin 2

Genetic polymorphisms:

• CYP2C9*2 or *3 variants increase bleeding risk and reduce dose requirements by 17-37% 2
• VKORC1 gene variants (especially -1639G>A) associated with lower dose requirements 2

Other endogenous factors 2:

• Hyperthyroidism
• Diarrhea/steatorrhea
• Poor nutritional state/vitamin K deficiency
• Cancer (increases odds of prolonged INR by 2.48-fold) 4
• Elevated temperature
• Blood dyscrasias
• Infectious hepatitis

Dietary and Lifestyle Factors

• Vitamin K intake changes: decreased intake potentiates warfarin 2
• Stress: physical or psychological stress can elevate INR through unknown mechanisms, possibly decreased warfarin metabolism 5
• Alcohol consumption: variable effects depending on pattern 2

Medication Changes Beyond Antibiotics

Drugs that increase INR 2:

• Amiodarone (very common in cardiac patients)
• Acetaminophen (high doses)
• Omeprazole/esomeprazole
• Tramadol
• Valproate
• Newer agents: erlotinib 6, ceftaroline 7, brexpiprazole 8

Herbal/botanical products 2:

• Garlic, Ginkgo biloba, dong quai, ginseng (antiplatelet/anticoagulant properties)
• St. John's wort (decreases INR)

Critical Clinical Considerations

For patients with left ventricular dysfunction specifically:

• Expect lower baseline warfarin requirements 3, 9
• Decompensation dramatically increases risk of supratherapeutic INR 4
• Post-LVAD patients require even lower doses (median 24.3 mg/week vs 35 mg/week pre-LVAD) 9

High-risk scenarios for prolonged INR elevation 4:

• Low steady-state warfarin dose requirement (odds ratio 0.87 per 10 mg weekly)
• Initial INR >6.0 (odds ratio 1.25 per unit increase)
• Active malignancy
• Advanced age

Common pitfalls:

• Failing to increase INR monitoring when initiating/discontinuing interacting medications in stable patients 1
• Not recognizing that timing matters: adding CYP2C9 inhibitor to stable warfarin causes more problems than starting warfarin on existing inhibitor 1
• Overlooking non-prescription botanicals and supplements 2
• Missing decompensated heart failure as a cause 4

Practical approach:

1. Review ALL medications (prescription, OTC, herbals) started/stopped in past 2 weeks
2. Assess for heart failure decompensation (especially relevant in this population)
3. Evaluate hepatic function
4. Check for intercurrent illness, fever, diarrhea
5. Assess dietary changes (vitamin K intake)
6. Consider stress/lifestyle changes
7. Review adherence patterns
8. In Asian patients, remember lower dose requirements 2